[Thrombolytic agents: efficacy in relation to evolution time and dose].
"In vitro" efficacy of urokinase (UK), streptokinase (SK) and tissue-type plasminogen activator (t-PA) was studied. Lytic action was measured by dry clot weight, 125I counts released from previously incorporated 125I-fibrinogen and fibrin fragment quantification at 1, 3 and 7 days using different doses. t-PA doses between 100 and 0.8 IU/ml were efficient. t-PA (40 IU/ml), SK (200 IU/ml) and UK (200 IU/ml) showed an equivalent activity in 1, 3 and 7 day-old clots. Fibrin fragment (D-D dimer) production was highest when t-PA and UK were used. "In vitro" lytic capacity up to 7 days after clot formation has been proved with the different fibrinolytic agents.
García Frade
L J
LJ
Torrado
M C
MC
Loren
M
M
Navarro
J L
JL
D001777:Blood Coagulation / Q000187:drug effects*; D004341:Drug Evaluation; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D013300:Streptokinase / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
Agentes trombolíticos: efectividad en relación con el tiempo de evolución y dosis.